Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR2 | O95136 | 3/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | PGD | P52209 | 1/20 | 0.32 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.31 |
| ▸ | PGK2 | P07205 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22367860 | 1.00 | S1PR2 (0.36) | S1PR2S1PR1S1PR3S1PR4PGD | |
| SCHEMBL30844210 | 0.90 | — | — | |
| Histidinol SCHEMBL1392278 | 0.80 | LAP3 (0.34) | — | |
| Histidinol SCHEMBL28208598 | 0.79 | LAP3 (0.33) | — | |
| SCHEMBL15947448 | 0.77 | S1PR1 (0.36) | S1PR2S1PR1S1PR3S1PR4S1PR5 | |
| SCHEMBL22656748 | 0.77 | KDM4E (0.33) | — | |
| SCHEMBL6553092 | 0.77 | KDM4E (0.33) | — | |
| Dexfosfoserine SCHEMBL6001968 | 0.76 | FOLH1 (0.32) | S1PR2S1PR1S1PR3S1PR4PGD | |
| SCHEMBL14874483 | 0.74 | MAP3K7 (0.30) | — | |
| Histidine SCHEMBL28923635 | 0.74 | SLC7A5 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 275 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120044159-A | Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application | 河北北方学院 | 2025-05-27 | — | — | CN | claimed |
| CN-115838700-A | L-histidinol phosphate aminotransferase mutant, coding gene, plasmid, genetic engineering bacteria and application | 南通紫琅生物医药科技有限公司 | 2023-03-24 | — | — | CN | claimed |
| EP-1461460-A4 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ASPARAGINE SYNTHASE, 5-AMINOLEVULINATE SYNTHASE, HISTIDINOL-PHOSPHATASE, 3-ISOPROPYLMALATE AND THREONINE SYNTHASE AS ANTIBIOTICS | ICORIA INC (US) | 2006-07-05 | — | — | EP | claimed |
| US-20060034817-A1 | Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase | UNIVERSITY OF SOUTH CAROLINA | 2006-02-16 | — | — | US | claimed |
| EP-1461460-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ASPARAGINE SYNTHASE, 5-AMINOLEVULINATE SYNTHASE, HISTIDINOL-PHOSPHATASE, 3-ISOPROPYLMALATE AND THREONINE SYNTHASE AS ANTIBIOTICS | Paradigm Genetics Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| EP-0688210-B1 | USE OF CARNOSINE IN COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 2004-02-25 | — | — | EP | claimed |
| WO-2003051295-A2 | NEUTRALIZATION OF STRATUM CORNEUM TO TREAT HYPERKERATOTIC SKIN LESIONS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-06-26 | — | — | WO | claimed |
| WO-2003050310-A2 | METHODS FOR THE IDENTIFICATION OF INHIBITORS OF ASPARAGINE SYNTHASE, 5-AMINOLEVULINATE SYNTHASE, HISTIDINOL-PHOSPHATASE, 3-ISOPROPYLMALATE AND THREONINE SYNTHASE AS ANTIBIOTICS | PARADIGM GENETICS, INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-20030113352-A1 | Neutralization of stratum corneum to treat hyperkeratotic skin lesions | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-06-19 | — | — | US | claimed |
| US-20020159976-A1 | Lactobacillus rhamnosus polynucleotides, polypeptides and methods for using them | VIALACTIA BIOSCIENCE (NZ) LIMITED (NZ) | 2002-10-31 | — | — | US | claimed |
| WO-2001077366-A1 | POSITIVE SELECTION METHOD, COMPOUNDS, HOST CELLS AND USES THEREOF | CUBIST PHARMACEUTICALS, INC. (US) | 2001-10-18 | — | — | WO | claimed |
| EP-0688210-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | Beiersdorf Aktiengesellschaft (DE) | 1995-12-27 | — | — | EP | claimed |
| WO-1994021245-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 1994-09-29 | — | — | WO | claimed |
| EP-4747382-A1 | COMPOSITIONS AND METHODS FOR MANAGEMENT OF WHITEFLY | Natural Resources Institute (GB) | 2026-05-27 | — | — | EP | disclosed |
| CN-120758362-B | Aspergillus DLF18 and application thereof | DALI UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-120758361-B | Mucor racemosus DLS157 and application thereof | 大理大学 | 2026-05-12 | — | — | CN | disclosed |
| WO-1995010629-A1 | A DETECTION SYSTEM FOR MUTAGENS THAT ALSO IDENTIFIES MUTAGENIC CHANGES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1995-04-20 | — | — | WO | disclosed |
| WO-1994021245-A1 | USE OF CARNOSINE OR A COMBINATION WITH UROCANIC ACID FOR TREATMENT OF PHOTODERMATOSES | BEIERSDORF AG (DE) | 1994-09-29 | — | — | WO | disclosed |
| WO-1994007994-A9 | INSULIN-DEPENDENT YEAST OR FUNGI | — | 1994-06-09 | — | — | WO | disclosed |
| WO-1994007994-A1 | INSULIN-DEPENDENT YEAST OR FUNGI | MCKENZIE MAUREEN A (US) | 1994-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060034817-A1 | Cloning, overexpression and therapeutic use of bioactive histidine ammonia lyase | HEXB, AHCYL1, HRH1 | S1PR2 3298/4885S1PR1 3004/4885S1PR3 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.